Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimoto, Takayuki, Mizoguchi, Izuru, Katagiri, Seiichiro, Tauchi, Tetsuzo, Furusawa, Jun-ichi, Chiba, Yukino, Mizuguchi, Junichiro, Ohyashiki, Junko H, Ohyashiki, Kazuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091524/
https://www.ncbi.nlm.nih.gov/pubmed/25057448
http://dx.doi.org/10.4161/onci.28861
_version_ 1782480777054781440
author Yoshimoto, Takayuki
Mizoguchi, Izuru
Katagiri, Seiichiro
Tauchi, Tetsuzo
Furusawa, Jun-ichi
Chiba, Yukino
Mizuguchi, Junichiro
Ohyashiki, Junko H
Ohyashiki, Kazuma
author_facet Yoshimoto, Takayuki
Mizoguchi, Izuru
Katagiri, Seiichiro
Tauchi, Tetsuzo
Furusawa, Jun-ichi
Chiba, Yukino
Mizuguchi, Junichiro
Ohyashiki, Junko H
Ohyashiki, Kazuma
author_sort Yoshimoto, Takayuki
collection PubMed
description Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive markers to identify these patients who can stop imatinib without relapse.
format Online
Article
Text
id pubmed-4091524
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40915242014-07-23 Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse Yoshimoto, Takayuki Mizoguchi, Izuru Katagiri, Seiichiro Tauchi, Tetsuzo Furusawa, Jun-ichi Chiba, Yukino Mizuguchi, Junichiro Ohyashiki, Junko H Ohyashiki, Kazuma Oncoimmunology Author's View Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive markers to identify these patients who can stop imatinib without relapse. Landes Bioscience 2014-05-14 /pmc/articles/PMC4091524/ /pubmed/25057448 http://dx.doi.org/10.4161/onci.28861 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Yoshimoto, Takayuki
Mizoguchi, Izuru
Katagiri, Seiichiro
Tauchi, Tetsuzo
Furusawa, Jun-ichi
Chiba, Yukino
Mizuguchi, Junichiro
Ohyashiki, Junko H
Ohyashiki, Kazuma
Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
title Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
title_full Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
title_fullStr Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
title_full_unstemmed Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
title_short Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
title_sort immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091524/
https://www.ncbi.nlm.nih.gov/pubmed/25057448
http://dx.doi.org/10.4161/onci.28861
work_keys_str_mv AT yoshimototakayuki immunosurveillancemarkersmaypredictpatientswhocandiscontinueimatinibtherapywithoutrelapse
AT mizoguchiizuru immunosurveillancemarkersmaypredictpatientswhocandiscontinueimatinibtherapywithoutrelapse
AT katagiriseiichiro immunosurveillancemarkersmaypredictpatientswhocandiscontinueimatinibtherapywithoutrelapse
AT tauchitetsuzo immunosurveillancemarkersmaypredictpatientswhocandiscontinueimatinibtherapywithoutrelapse
AT furusawajunichi immunosurveillancemarkersmaypredictpatientswhocandiscontinueimatinibtherapywithoutrelapse
AT chibayukino immunosurveillancemarkersmaypredictpatientswhocandiscontinueimatinibtherapywithoutrelapse
AT mizuguchijunichiro immunosurveillancemarkersmaypredictpatientswhocandiscontinueimatinibtherapywithoutrelapse
AT ohyashikijunkoh immunosurveillancemarkersmaypredictpatientswhocandiscontinueimatinibtherapywithoutrelapse
AT ohyashikikazuma immunosurveillancemarkersmaypredictpatientswhocandiscontinueimatinibtherapywithoutrelapse

Ejemplares similares